-
effectivehealthcare.ahrq.gov/products/grant-manuscripts/clinical-trial-registrations-abstract
-
effectivehealthcare.ahrq.gov/products/clinical-care/rapid-research
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-appendix-f.xlsx
October 08, 2025 - Risk of bias assessment for cohort studies
Author, Year Did the study attempt to enroll all (or a random
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management-1_research.pdf
July 01, 2012 - The
value of this approach in the ambulatory setting has been demonstrated in several studies.
-
effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
December 29, 2015 - However, the experts wanted to see additional clinical studies that
compare the efficacy of secukinumab … However, the experts thought that more clinical studies are needed to
determine the long-term efficacy … were concerned about the reported
adverse events.15,18 Some experts also wanted to see more clinical studies … of patients with complete tophus resolution.28 The most common adverse events reported in
the two studies … Novartis AIN457 (secukinumab) meets
primary endpoint in two phase III studies in
ankylosing spondylitis
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-quality-indicator-testing_research.pdf
April 01, 2010 - The goal was to determine a common robust
quality indicator set for future comparative studies and quality
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/glucocorticoid-injections_clinician.pdf
June 01, 2016 - A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians
A Randomized Trial of Epidural Glucocorticoid
Injections for Spinal Stenosis: A Brief Summary
of Findings for Clinicians
KEY CLINICAL ISSUE
What are the relative effectiveness and adverse effect…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-prepub-final-research-table-rct.xlsx
May 29, 2025 - RCT
Author, year Is randomization adequate?
Yes/No/Unclear Is allocation concealment adequate?
Yes/No/Unclear Are groups similar at baseline?
Yes/No/Unclear Is the outcome assessor (interviewer) masked?
Yes/No/Unclear Is the data analyst masked?
Yes/No/Unclear Are attrition and crossovers reported?
Yes/No/Uncl…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
October 08, 2025 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-glucose-control_research.pdf
July 01, 2010 - sulfonylurea.”3 This twice daily injectable drug is approved for
use only in adults, pending pediatric studies
-
effectivehealthcare.ahrq.gov/products/outcomes-nutrition/research
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-report-creating-efficiencies-extraction-data.pdf
August 01, 2021 - bPertains to the studies where the data element was identified as reported in the study by the human … cPertains to the studies where the data element was correctly identified as reported in the study by … Sentence
1 Participants were randomly assigned to an experimental group or a comparison group (24
studies
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
October 08, 2025 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/01_-arthritis_potential_high_impact_june_2012.pdf
January 01, 2012 - However, one clinical expert stated that double-blind studies are needed to compare
MSC therapy to … cartilage regeneration, evaluated by magnetic resonance
imaging, would need to be shown by these studies … janus
kinase inhibitor, in the treatment of
rheumatoid arthritis: open-label, long-term
extension studies
-
effectivehealthcare.ahrq.gov/sites/default/files/11_pepticulcer_potential_high_impact_june_2012.pdf
January 01, 2012 - Reports from observational
studies suggested that helminths might prevent or improve UC by inducing … common and that people with helminths have an altered immunologic response to antigens.
2
Preclinical studies … relief at initial followup.
25
POEM has been
generally well tolerated according to reports from studies
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-276-ocd-appendix-g.xlsx
January 01, 2022 - child and adolescent anxiety center at Mayo Clinic + community controls: participated in two previous studies … : We should discuss studies that enroll at least one clinical sample, e.g.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-foot-ulcer-amputation-prevalence_research.pdf
February 01, 2011 - initial observations, algorithm 3, which is consistent with the
definition of diabetes in many previous studies
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/pharma-nonpharma-ptsd-2022-update-app-g1.xlsx
January 01, 2022 - Risk of Bias 2 assessment of new included studies
RoB Domain Bias Due to Randomization (Cochrane) or
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
October 08, 2025 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/products/ptsd-pharm-non-pharm-treatment-update/protocol